Nindhana Paranthaman, MBA '15

Nindhana Paranthaman is a physician executive at Summit Therapeutics leading clinical development strategy for new indications of ivonescimab, a first‐in‐class investigational anti-PD‐1 x VEGF bispecific antibody. She has over a decade of experience in biopharma with previous leadership roles at Exelixis, Genentech, Amgen, and Bristol‐Myers Squibb, contributing to the development and commercialization of novel therapies for solid tumors and autoimmune diseases. Nindhana holds a medical degree from Sri Ramachandra Institute of Higher Education and Research and an MBA in Health Care Management and Marketing from Johns Hopkins Carey Business School. She is an active speaker, mentor, startup advisor and a champion of diversity, equity, and inclusion in the industry.